This is the authors' abstract. We don't add key points for this paper.
Benign prostatic hyperplasia (BPH) is a prevalent condition among middle-aged and elderly men, often causing lower urinary tract symptoms (LUTS). Current treatment options encompass watchful waiting, pharmacological therapy, and surgical intervention. Among these, surgical treatment rapidly alleviates LUTS and enhances quality of life, making it the most effective approach for moderate to severe BPH. In recent years, with the rapid development and clinical application of various laser technologies, transurethral resection of the prostate (TURP), once considered the "gold standard," has faced controversies due to its higher surgical morbidity and limitations in treating large prostate volumes. Laser technologies, with their remarkable surgical efficacy, safety, and reduced morbidity, have increasingly gained favor among clinicians. This article primarily delves into the clinical advancements of diode laser minimally invasive technology in BPH treatment, aiming to provide a theoretical basis for clinicians in addressing clinical challenges.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: